Adults with plaque PsO who received continuous icotrokinra had superior efficacy outcomes when compared with those who switched to placebo.

Topical ruxolitinib cream 1.5% for 24 weeks was significantly associated with disease improvement among patients with prurigo nodularis.

Delgocitinib cream 20mg/g significantly improves the sign and symptoms of chronic hand eczema among adolescent patients compared with vehicle cream.

High doses of temtokibart — including 600 mg, 450 mg, and 300 mg — contributed to significant improvements in disease severity in patients with AD.

Levels of systemic inflammatory markers were reduced following 16 weeks of secukinumab treatment in patients with moderate to severe HS.

Presenting research from the annual meeting of the European Academy of Dermatology and Venereology. Dermatology Advisor, a trusted source of medical news and feature content for healthcare providers, ...